Intellia Therapeutics

NTLA · NASDAQ

$11.84+$0.26 (+2.25%)TodayMarket closed · Oct 20, 7:57 PM ET

Prev close $11.58

Latest news

Press releaseOct 13, 7:30 AM ETGlobe Newswire
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer
NewsOct 8, 9:53 AM ETAvi Kapoor
Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday
NewsOct 6, 11:46 AM ETChandrima Sanyal
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
NewsOct 5, 6:28 AM ET
Intellia Therapeutics Q2 2026 Earnings Call Transcript
Press releaseSep 8, 8:00 AM ETGlobe Newswire
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Press releaseSep 4, 8:50 AM ETGlobe Newswire
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
NewsSep 3, 10:13 AM ETChandrima Sanyal
Cathie Wood Trims 40K Shopify Shares After August Rally: Where ARK Is Reinvesting?
Press releaseAug 6, 7:00 AM ETGlobe Newswire
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
NewsJul 10, 11:30 AM ETVandana Singh
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain
NewsJun 29, 11:14 AM ETErica Kollmann
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED)
NewsJun 17, 10:11 AM ETAvi Kapoor
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday
NewsJun 15, 9:39 AM ETVandana Singh
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
Press releaseJun 13, 7:30 AM ETGlobe Newswire
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Press releaseJun 1, 7:30 AM ETGlobe Newswire
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
Press releaseMay 11, 7:30 AM ETGlobe Newswire
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
NewsApr 29, 8:06 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsApr 29, 8:03 AM ETAvi Kapoor
Robinhood Posts Downbeat Q1 Results, Joins Enphase Energy, Avis Budget And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
NewsApr 27, 10:07 AM ETVandana Singh
Intellia Therapeutics FDA Rolling Application For Gene Therapy Puts Hype To Test
Press releaseApr 8, 9:15 AM ETGlobe Newswire
The Credibility Filter Wall Street Uses to Sort Biotech Winners
Press releaseMar 3, 9:00 AM ETPRNewswire
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
NewsMar 3, 7:01 AM ET
Demystifying Intellia Therapeutics: Insights From 4 Analyst Reviews
NewsMar 2, 10:05 AM ETVandana Singh
Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial
Press releaseFeb 26, 7:30 AM ETGlobe Newswire
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
NewsFeb 26, 6:11 AM ET
Earnings Scheduled For February 26, 2026
NewsFeb 25, 1:02 PM ET
Earnings Preview For Intellia Therapeutics
NewsJan 28, 4:01 PM ET
Breaking Down Intellia Therapeutics: 11 Analysts Share Their Views
Press releaseJan 28, 8:05 AM ETGlobe Newswire
Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine
NewsJan 27, 1:03 PM ETVandana Singh
Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder
NewsJan 16, 12:35 PM ET
10 Health Care Stocks With Whale Alerts In Today's Session
Press releaseNov 18, 8:45 AM ETGlobe Newswire
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
NewsNov 11, 6:45 AM ET
What 21 Analyst Ratings Have To Say About Intellia Therapeutics
NewsNov 7, 12:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsNov 7, 7:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press releaseNov 6, 4:00 PM ETGlobe Newswire
Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates
NewsOct 30, 8:08 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NewsOct 30, 7:16 AM ET
Market-Moving News for October 30th
NewsOct 29, 5:57 PM ETAdam Eckert
Intellia Therapeutics Stock Is Diving Again: Here's Why
NewsOct 28, 7:48 AM ETAvi Kapoor
Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday
NewsOct 28, 7:23 AM ETAvi Kapoor
This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
NewsOct 27, 1:03 PM ETAvi Kapoor
Gold Falls 3%; Carter's Shares Gain After Q3 Earnings
NewsOct 1, 9:57 AM ETAvi Kapoor
Acuity, Lithium Americas, Rezolve AI, AES And Other Big Stocks Moving Higher On Wednesday
NewsSep 18, 10:19 AM ETAvi Kapoor
Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer

Helen Of Troy Posts Upbeat Q2 Earnings, Joins Pacira Biosciences, Wolfspeed And Other Big Stocks Moving Higher On Thursday

Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up

Intellia Therapeutics Q2 2026 Earnings Call Transcript

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)

Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million

Cathie Wood Trims 40K Shopify Shares After August Rally: Where ARK Is Reinvesting?

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED)

Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Robinhood Posts Downbeat Q1 Results, Joins Enphase Energy, Avis Budget And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Intellia Therapeutics FDA Rolling Application For Gene Therapy Puts Hype To Test

The Credibility Filter Wall Street Uses to Sort Biotech Winners

Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

Demystifying Intellia Therapeutics: Insights From 4 Analyst Reviews

Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Earnings Scheduled For February 26, 2026

Earnings Preview For Intellia Therapeutics

Breaking Down Intellia Therapeutics: 11 Analysts Share Their Views

Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine

Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder

10 Health Care Stocks With Whale Alerts In Today's Session

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

What 21 Analyst Ratings Have To Say About Intellia Therapeutics

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Market-Moving News for October 30th

Intellia Therapeutics Stock Is Diving Again: Here's Why

Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday

This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Gold Falls 3%; Carter's Shares Gain After Q3 Earnings

Acuity, Lithium Americas, Rezolve AI, AES And Other Big Stocks Moving Higher On Wednesday

Radian Group, Intel, Nanobiotix, CrowdStrike And Other Big Stocks Moving Higher On Thursday